R. A. Wolfe, V. B. Ashby, E. L. Milford, A. O. Ojo, R. E. Ettenger et al., Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, N Engl J Med. 2 déc, vol.341, issue.23, pp.1725-1755, 1999.

J. R. Silkensen, Long-Term Complications in Renal Transplantation, J Am Soc Nephrol. 3 janv, vol.11, issue.3, pp.582-590, 2000.

F. Fowkes, J. F. Price, and F. Fowkes, Incidence of diagnosed deep vein thrombosis in the general population: systematic review, Eur J Vasc Endovasc Surg. janv, vol.25, issue.1, pp.1-5, 2003.

K. C. Abbott, D. F. Cruess, L. Agodoa, E. S. Sawyers, and D. P. Tveit, Early renal insufficiency and late venous thromboembolism after renal transplantation in the United States, Am J Kidney Dis. janv, vol.43, issue.1, pp.120-150, 2004.

J. A. Heit, Epidemiology of venous thromboembolism, Nat Rev Cardiol. août, vol.12, issue.8, pp.464-74, 2015.

H. Decousus, I. Quéré, E. Presles, F. Becker, M. Barrellier et al., Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study, Ann Intern Med. 16 févr, vol.152, issue.4, pp.218-242, 2010.

J. A. López and J. Chen, Pathophysiology of venous thrombosis, Thromb Res, vol.123, pp.30-34, 2009.

S. Parajuli, J. B. Lockridge, E. D. Langewisch, D. J. Norman, and J. L. Kujovich, Hypercoagulability in Kidney Transplant Recipients, Transplantation. avr, vol.100, issue.4, pp.719-745, 2016.

A. Kazory and D. Ducloux, Acquired hypercoagulable state in renal transplant recipients, Thromb Haemost. avr, vol.91, issue.4, pp.646-54, 2004.

L. Julien, P. P. Roux, and . Mtor, médecine/sciences. déc, vol.26, issue.12, pp.1056-60, 2010.

. Ct-14360_certican_pis_ri_avis2_ct14360,

D. Sur,

G. A. Knoll, M. B. Kokolo, R. Mallick, A. Beck, C. D. Buenaventura et al., Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data, BMJ, vol.349, p.6679, 2014.

, Résumé des caractéristiques du produit -CERTICAN 0,1 mg

M. C. Baas, V. Gerdes, T. Berge, I. Heutinck, K. M. Florquin et al., Treatment with everolimus is associated with a procoagulant state, Thromb Res. août, vol.132, issue.2, pp.307-318, 2013.

A. Babinska, M. S. Markell, M. O. Salifu, M. Akoad, Y. H. Ehrlich et al., Enhancement of human platelet aggregation and secretion induced by rapamycin, Nephrol Dial Transplant. déc, vol.13, issue.12, pp.3153-3162, 1998.

R. M. Langer and B. D. Kahan, Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients, Transplantation. 27 juill, vol.76, issue.2, pp.318-341, 2003.

K. Budde, F. Lehner, C. Sommerer, P. Reinke, W. Arns et al., Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study, Am J Transplant. janv, vol.15, issue.1, pp.119-147, 2015.

F. J. Bemelman, J. W. De-fijter, J. Kers, C. Meyer, H. Peters-sengers et al., Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial, Am J Transplant, vol.17, issue.4, pp.1020-1050, 2017.

H. Holdaas, L. Rostaing, D. Serón, C. E. Chapman, J. Fellstrøm et al., Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study, Transplantation. 27 août, vol.92, issue.4, pp.410-418, 2011.

H. Ekberg, H. Tedesco-silva, A. Demirbas, ?. Vítko, B. Nashan et al., Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, N Engl J Med. 20 déc, vol.357, issue.25, pp.2562-75, 2007.

F. P. Schena, M. D. Pascoe, J. Alberu, M. Del-carmen-rial, R. Oberbauer et al., Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial, Transplantation. 27 janv, vol.87, issue.2, pp.233-275, 2009.

J. Pascual, S. P. Berger, O. Witzke, H. Tedesco, S. Mulgaonkar et al., Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation, J Am Soc Nephrol JASN. juill, vol.29, issue.7, pp.1979-91, 2018.

K. Keller, C. Daniel, H. Schöcklmann, K. Endlich, D. Kerjaschki et al., Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not longterm recovery in experimental thrombotic microangiopathy, Nephrol Dial Transplant, vol.21, issue.10, pp.2724-2759, 2006.

H. Sartelet, O. Toupance, M. Lorenzato, F. Fadel, L. H. Noel et al., Sirolimusinduced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys, Am J Transplant. oct, vol.5, issue.10, pp.2441-2448, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00086023

M. Robson, I. Côte, I. Abbs, G. Koffman, and D. Goldsmith, Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?, Am J Transplant. mars, vol.3, issue.3, pp.324-331, 2003.

F. Nava, G. Cappelli, G. Mori, M. Granito, G. Magnoni et al., Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation, Transplant Proc. sept, vol.46, issue.7, pp.2263-2271, 2014.

D. Cibrik, H. T. Silva, A. Vathsala, E. Lackova, C. Cornu-artis et al., Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation, Transplantation. 15 avr, vol.95, issue.7, pp.933-975, 2013.

F. S. Shihab, D. Cibrik, L. Chan, Y. S. Kim, M. Carmellini et al., Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine, Clin Transplant. avr, vol.27, issue.2, pp.217-243, 2013.

E. Paoletti, L. Marsano, D. Bellino, P. Cassottana, and G. Cannella, Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial, Transplantation. 15 mars, vol.93, issue.5, pp.503-511, 2012.

L. Fischer, F. Saliba, G. M. Kaiser, D. Carlis, L. Metselaar et al., Threeyear Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study, Transplantation. juill, vol.99, issue.7, pp.1455-62, 2015.

. Zinbryta-(daclizumab), . Mirena, and V. Facteurs, retour d'information sur le PRAC de juin 2017 -Point d'information -ANSM : Agence nationale de sécurité du médicament et des produits de santé

J. T. Thibodeau, J. D. Mishkin, P. C. Patel, P. A. Kaiser, C. R. Ayers et al., Sirolimus use and incidence of venous thromboembolism in cardiac transplant recipients, Clin Transplant. déc, vol.26, issue.6, pp.953-962, 2012.

R. J. Alvarez-alvarez, E. Barge-caballero, S. A. Chavez-leal, M. J. Paniagua-martin, R. Marzoa-rivas et al., Venous thromboembolism in heart transplant recipients: Incidence, recurrence and predisposing factors, J Heart Lung Transplant. 1 févr, vol.34, issue.2, pp.167-74, 2015.

M. Morice, P. W. Serruys, J. E. Sousa, J. Fajadet, B. Hayashi et al., A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization, N Engl J Med. 6 juin, vol.346, issue.23, pp.1773-80, 2002.

R. Lingaraju, N. P. Blumenthal, J. Mendez, O. Hadjiliadis, J. C. Lee et al., Venous Thromboembolic Disease after Lung Transplantation: Special Focus on Sirolimus. Open Transplant J [Internet, vol.18, issue.2010

V. N. Ahya, P. J. Mcshane, M. A. Baz, V. G. Valentine, S. M. Arcasoy et al., Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation, J Heart Lung Transplant. févr, vol.30, issue.2, pp.175-81, 2011.

M. Montalbano, G. W. Neff, N. Yamashiki, D. Meyer, M. Bettiol et al., A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications, Transplantation. 27 juill, vol.78, issue.2, pp.264-272, 2004.

M. Molinari, K. Berman, G. Meeberg, J. A. Shapiro, D. Bigam et al., Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients, Transpl Int. févr, vol.23, issue.2, pp.155-68, 2010.

C. Toso, G. A. Meeberg, D. L. Bigam, J. Oberholzer, A. Shapiro et al., De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects, Transplantation. 15 mai, vol.83, issue.9, pp.1162-1170, 2007.

A. Kazory, D. Ducloux, A. Coaquette, P. Manzoni, and J. Chalopin, Cytomegalovirusassociated venous thromboembolism in renal transplant recipients: a report of 7 cases, vol.77, pp.597-606, 2004.

D. Imberti, G. Agnelli, W. Ageno, M. Moia, G. Palareti et al., Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry, Haematologica. févr, vol.93, issue.2, pp.273-281, 2008.

J. W. Blom, C. Doggen, S. Osanto, and F. R. Rosendaal, Malignancies, prothrombotic mutations, and the risk of venous thrombosis, JAMA. 9 févr, vol.293, issue.6, pp.715-737, 2005.

J. A. Heit, W. M. O'fallon, T. M. Petterson, C. M. Lohse, M. D. Silverstein et al., Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study, Arch Intern Med. 10 juin, vol.162, issue.11, pp.1245-1253, 2002.

D. P. Cronin-fenton, F. Søndergaard, L. A. Pedersen, J. P. Fryzek, K. Cetin et al., Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, Br J Cancer. 28 sept, vol.103, issue.7, pp.947-53, 1997.

J. F. Timp, S. K. Braekkan, H. H. Versteeg, and S. C. Cannegieter, Epidemiology of cancerassociated venous thrombosis, Blood. 5 sept, vol.122, issue.10, pp.1712-1735, 2013.

H. K. Chew, T. Wun, D. Harvey, H. Zhou, and R. H. White, Incidence of venous thromboembolism and its effect on survival among patients with common cancers, Arch Intern Med. 27 févr, vol.166, issue.4, pp.458-64, 2006.

J. M. Campistol, J. Eris, R. Oberbauer, P. Friend, B. Hutchison et al., Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation, J Am Soc Nephrol JASN. févr, vol.17, issue.2, pp.581-590, 2006.

H. M. Kauffman, W. S. Cherikh, M. A. Mcbride, Y. Cheng, and D. W. Hanto, Post-transplant de novo malignancies in renal transplant recipients: the past and present, Transpl Int Off J Eur Soc Organ Transplant. août, vol.19, issue.8, pp.607-627, 2006.

S. Euvrard, E. Morelon, L. Rostaing, E. Goffin, A. Brocard et al., Sirolimus and secondary skin-cancer prevention in kidney transplantation, N Engl J Med. 26 juill, vol.367, issue.4, pp.329-368, 2012.

G. Stallone, A. Schena, B. Infante, D. Paolo, S. Loverre et al., Sirolimus for Kaposi's sarcoma in renal-transplant recipients, N Engl J Med. 31 mars, vol.352, issue.13, pp.1317-1340, 2005.

R. Salgo, J. Gossmann, H. Schöfer, H. G. Kachel, J. Kuck et al., Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial, Am J Transplant. juin, vol.10, issue.6, pp.1385-93, 2010.

J. Alberú, M. D. Pascoe, J. M. Campistol, F. P. Schena, M. Rial et al., Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial, Transplantation. 15 août, vol.92, issue.3, pp.303-313, 2011.

, Fiche info -AFINITOR 10 mg, comprimé -Base de données publique des médicaments

D. Sur,

C. Ponticelli, M. Moia, and G. Montagnino, Renal allograft thrombosis, Nephrol Dial Transplant. 1 mai, vol.24, issue.5, pp.1388-93, 2009.

K. El-zorkany, J. Bridson, A. Sharma, and A. Halawa, Transplant Renal Vein Thrombosis, Exp Clin Transplant. avr, vol.15, issue.2, pp.123-132, 2017.

N. Bakir, W. J. Sluiter, R. J. Ploeg, W. J. Van-son, and A. M. Tegzess, Objective: Everolimus is an immunosupressive agent used in kidney transplantation. its use is associated with a biological procoagulant state. We studied the potential association of everolimus with the risk of veinous thromboembolic events (VTE), Nephrol Dial Transplant Abstract

, We evaluated two cohorts, one treated with everolimus (« Imtor + » cohort) and the other without (control group). The diagnosis of VTE was assessed by hospitalisation records. The monitoring period began at the introduction of everolimus for the first cohort, and at the date of kidney transplantation for the second and finished at the last medical contact for both, Study design: We conducted a monocentric retrospective study in renal transplant recipients in Amiens, 2017.

, Results: There were 117 patients in the « Imtor + » cohort and 234 patients in the control cohort. VTE was more fréquent in the first group (12,8% versus 5,9%; p = 0,028). In a multivarate model, VTE was independently associated with BMI (HR = 1,079

, 044) Conclusion: The use of everolimus is independently associated with VTE, p.0

, Keywords: venous thromboembolism, everolimus, kidney transplantation, retrospective study, adverse effects